免疫检查点抑制剂相关心肌炎研究进展

Research progress of inhibitor associated myocarditis at immune checkpoint

免疫检查点抑制剂(ICIs)用于肿瘤患者是肿瘤治疗方法上的一大突破性进展。但随着越来越多的肿瘤患者接受免疫检查点抑制剂的治疗,一系列与免疫检查点抑制剂相关的不良反应也显现出来。其中免疫检查点抑制剂相关性心肌炎虽然发病率低,但致死率极高。因此,现就免疫检查点抑制剂相关心肌炎的发病情况、发病机制、危险因素、诊断及治疗作一综述。

The use of immunocheckpoint inhibitors(ICIs) in cancer patients is a breakthrough in cancer therapy. However, with more and more cancer patients receiving immunocheckpoint inhibitors, a series of adverse reactions related to immunocheckpoint inhibitors have also emerged. Although the incidence of inhibitor associated myocarditis at immune checkpoint is low, the mortality rate is very high. Therefore, this article reviews the pathogenesis, risk factors, diagnosis and treatment of inhibitor related myocarditis at immune checkpoint.